GlassScriptPhysician profile
Adina Pascaru
NPI 1275518862
$4,686.82
in general payments reported to CMS, 2019-2025
29 companies · $619 in 2025
The $619 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $283 · 2021: $835 · 2022: $801 · 2023: $841 · 2024: $551 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,011.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $760.77 | 2019-2025 | |
| Amgen INC. | $648.03 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $490.55 | 2019-2023 | Xarelto |
| Pfizer INC. | $444.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $348.83 | 2019-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $316.40 | 2019-2025 | Breyanzi |
| Merck Sharp & Dohme LLC | $252.57 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.93 | 2019-2023 | Jardiance |
| Boston Scientific Corporation | $209.50 | 2019-2025 | Watchman Flx, Watchman Access System |
| Cvrx, INC. | $130.18 | 2024-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $100.23 | 2019-2023 | |
| Abbott Laboratories | $97.73 | 2019-2023 | Aveir |
| Regeneron Healthcare Solutions, INC. | $82.57 | 2019 | |
| Althera Pharmaceuticals LLC | $71.06 | 2021-2022 | |
| Inspire Medical Systems, INC. | $69.12 | 2025 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $46.69 | 2022-2025 | Telepatch Cardiac Monitor |
| Medtronic, INC. | $42.71 | 2024 | Cobalt Dr Mri Surescan |
| Lilly USA, LLC | $42.40 | 2019-2025 | Mounjaro, Zepbound |
| Lexicon Pharmaceuticals, INC. | $40.86 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $36.86 | 2021 | |
| Esperion Therapeutics, INC. | $36.29 | 2024-2025 | Nexletol |
| Philips North America LLC | $31.72 | 2023 | |
| Kestra Medical Technology Services, INC. | $27.97 | 2022 | |
| Irhythm Technologies, INC. | $26.31 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $26.13 | 2025 | |
| Heartflow, INC. | $23.50 | 2022 | |
| Vifor Pharma, INC. | $19.74 | 2019 | |
| Ionis Pharmaceuticals, INC. | $14.50 | 2025 | Tryngolza |
| Infobionic, INC | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adina Pascaru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.